Depression in adolescents is common, and treatment outcomes are often not as good as clinicians would like. It has not been clear whether starting with fluoxetine alone, or fluoxetine combined with cognitive behavioural therapy (CBT), gives better results, and even less is known about what to do next if the first treatment does not work well enough.
A pragmatic clinical trial addressed both questions. Adolescents with major depressive disorder could choose fluoxetine alone or fluoxetine plus CBT as an initial treatment. Those who did not respond were then randomly assigned either to switch to a different antidepressant, sertraline, vortioxetine or duloxetine, or to add a second medication to their fluoxetine, aripiprazole, olanzapine or lithium.
The main finding was that none of these strategies stood out as clearly better than the others in overall response rates or safety. Combining fluoxetine with CBT from the outset showed no significant advantage over fluoxetine alone. In smaller, exploratory comparisons, adding olanzapine was linked to better sleep quality than switching to duloxetine, and adding aripiprazole was linked to better quality of life than switching to duloxetine.
All approaches tested were feasible and acceptable to use. If your teenager is struggling with depression, an assessment with a psychologist is a useful starting point, alongside their GP.
What the trial tested
Major depressive disorder in adolescents is common, and treatment results often fall short of what clinicians and families hope for. Two questions have remained unresolved: whether starting treatment with the antidepressant fluoxetine alone gives similar results to starting with fluoxetine combined with cognitive behavioural therapy (CBT), and what to do next when a first medication does not work well enough.
This pragmatic, multistep, multicentre trial addressed both questions in one design. In the first step, adolescents with major depressive disorder could choose between fluoxetine alone or fluoxetine combined with CBT. In the second step, those who had not responded to the first treatment were randomised to either switch to a different antidepressant, sertraline, vortioxetine or duloxetine, or to add a second medication on top of fluoxetine, aripiprazole, olanzapine or lithium. The main outcome measured was the response rate, alongside secondary measures covering depression, anxiety, overall symptom severity, sleep quality and quality of life, and safety measures covering mania, suicidality and adverse events.
What it found
Across the different treatment strategies tested, there were no significant differences in the main response rate outcome or in adverse events. No strategy stood out. Starting with fluoxetine combined with CBT showed no significant advantage over starting with fluoxetine alone, at least in this trial.
In smaller, exploratory comparisons within the second step, augmenting fluoxetine with olanzapine was associated with greater improvement in sleep quality than switching to duloxetine, a pattern that held up in additional post hoc comparisons. Augmenting fluoxetine with aripiprazole was associated with greater improvement in quality of life than switching to duloxetine. All strategies tested in the second step were feasible and acceptable to patients, the authors report.
Why it matters
For families and clinicians facing the common situation of a teenager not responding well enough to an initial antidepressant, this trial does not identify one clearly superior next step. What it does show is that a structured, sequential approach to treatment, trying an initial option and then either switching or adding a second medication based on response, is practical to carry out and acceptable to young people. The exploratory findings around sleep quality and quality of life may help guide individual decisions, but the authors are careful to describe these as exploratory rather than definitive.
Its limits
The trial itself notes a small sample size and the absence of a control group and blinding as limitations, which is common in pragmatic trials designed to reflect real-world treatment choices rather than tightly controlled conditions. The authors frame their results as supporting the feasibility of this sequential treatment approach, and as a basis for future, more adequately powered trials, rather than as a final answer about which strategy works best.
If your teenager is showing signs of depression, whether newly or after an earlier treatment has not fully helped, an assessment with a psychologist is a useful starting point, working alongside their GP or prescribing doctor.